A
Aymen I. Idris
Researcher at University of Sheffield
Publications - 70
Citations - 2184
Aymen I. Idris is an academic researcher from University of Sheffield. The author has contributed to research in topics: Osteoclast & Osteoblast. The author has an hindex of 21, co-authored 69 publications receiving 1878 citations. Previous affiliations of Aymen I. Idris include University of Aberdeen & Edinburgh Cancer Research Centre.
Papers
More filters
Journal ArticleDOI
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors
Aymen I. Idris,Aymen I. Idris,Rob van't Hof,Rob van't Hof,Iain R. Greig,Susan A Ridge,David Baker,Ruth A. Ross,Stuart H. Ralston,Stuart H. Ralston +9 more
TL;DR: The studies show that the CB1 receptor has a role in the regulation of bone mass and ovariectomy-induced bone loss and that CB1- and CB2-selective cannabinoid receptor antagonists are a new class of osteoclast inhibitors that may be of value in the treatment of osteoporosis and other bone diseases.
Journal ArticleDOI
Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro
TL;DR: It is concluded that aminobisphosphonates cause osteoblast apoptosis in vitro at micromolar concentrations and inhibit osteoblasts differentiation at nanomolar concentrations by mechanisms that are independent of effects on protein prenylation and may be due in part to inhibition of mineralization.
Journal ArticleDOI
Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells
Aymen I. Idris,Antonia Sophocleous,Euphemie Landao-Bassonga,Meritxell Canals,Graeme Milligan,David Baker,Rob van't Hof,Stuart H. Ralston +7 more
TL;DR: The CB1 receptor is unique in that it regulates peak bone mass through an effect on osteoclast activity, but protects against age-related bone loss by regulating adipocyte and osteoblast differentiation of bone marrow stromal cells.
Journal ArticleDOI
Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor
TL;DR: The observations indicate that CB2 regulates osteoclast formation and contributes to ovariectomy-induced bone loss and demonstrate that cannabinoid receptor antagonists/inverse agonists may be of value in the treatment of bone diseases characterized by increased osteOClast activity.
Journal ArticleDOI
The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo
TL;DR: It is concluded that pharmacological blockade of TRPV1 ion channels by capsazepine inhibits osteoclastic bone resorption and protects against ovariectomy induced bone loss in mice, but also inhibits osteoblast activity and bone formation.